HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

903.801

-21.668-2.34%

Number of Gainers:1

Number of Losers:16

Number of Flat:- -

PE:- -

High:917.158

Open:911.479

Low:888.965

Close:925.469

Volume:163.58M

Turnover:1.36B

Market Cap:610.82B

Float Cap:505.13B

Loading ...

GenFleet-B (02595) Spends HK$3.1855 Million to Repurchase 116,000 Shares on September 28

Sino Biopharma Unit Grants STADA Commercialization License for Pembrolizumab Biosimilar

MT Newswires Live

Sino Biopharmaceutical - Stada to Hold Marketing Authorizations and Sales Rights in Licensed Territory, Options for US and GCC

THOMSON REUTERS

Sino Biopharmaceutical - Enter into Strategic Biosimilars Partnership with Stada

THOMSON REUTERS

Sino Biopharmaceutical - Cttq Grants Stada Exclusive License for Pembrolizumab Biosimilar in EU, Switzerland, UK, CIS

THOMSON REUTERS

Sino Biopharmaceutical Stock Slides 1.3% in Hong Kong, Underperforms Competitors

JD Health International Stock Rises 1.3% in Hong Kong

Healthcare Shows Resilience! Pharma ETF Huabao (562050) Rises Against the Market, Livzon Pharmaceutical Group Hits Limit Up! Medical Devices Show Localized Strength, Mindray and United Imaging Advance Together

Fosun Pharma Spends HK$1.0805 Million to Repurchase 62,000 Shares on September 25

Lazard Asset Management LLC Trims 738,800 Shares in Sinopharm (01099) at Approximately HK$15.1 Per Share

FMR LLC Trims Sinopharm Stake by 732,400 Shares at About HK$15.01 Each

JD Health International Stock Sheds 2.0% in Hong Kong

Regulator Clarifies Insurers' Hong Kong Stock Connect ETF Investment Rules; Crealights' Southbound Stake Rises to 4.2%

CSPC Pharmaceutical Says Phase III Trial of Becotatug Achieves Positive Topline Results

CSPC Pharma's Phase III Trial of Lung Cancer Drug Combo Achieves Positive Topline Results

MT Newswires Live

CSPC Pharma's JMT101 Combined with Osimertinib Achieves Positive Topline Results in Phase III Trial for First-Line Treatment of EGFR ex20ins NSCLC

CSPC Pharmaceutical - Phase Iii Trial of Becotatug (Jmt101) with Osimertinib Achieves Positive Topline Results

THOMSON REUTERS

Dizal Pharmaceutical Executives Including CFO Lu Hongbin Plan to Reduce Shareholdings

CSPC Pharm Begins Phase III Breast Cancer Drug Trial

MT Newswires Live

Hubei Tycoon Ai Luming Detained: Who Is Hurt by Tiangan Asset Management's 3.5 Billion Yuan Debt?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/BK1515/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":903.80066,"timestamp":1790928487328,"preClose":925.4686,"halted":0,"volume":163580359,"delay":0,"changeRate":-0.023413,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-21.667969,"latestTime":"10-02 16:00:00","open":911.47943,"high":917.1582,"low":888.9653,"amount":1358372536,"amplitude":0.030463,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791163800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1790904600000,1790913600000],[1790917200000,1790928000000]],"pbRate":1.399902,"peRate":18.141358,"turnoverRate":0.002066,"increases":1,"decrements":16,"flats":0,"marketCap":610824762624,"floatMarketCap":505133911680},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":917.1582,"amplitude":0.030463,"preClose":925.4686,"low":888.9653,"pbRate":"1.399902","latestPrice":903.80066,"volume":163580359,"delay":0,"open":911.47943,"prevYearClose":1190.107,"prevWeekClose":893.286,"prevMonthClose":925.469,"prevQuarterClose":925.469,"fiveDayClose":900.278,"twentyDayClose":925.365,"sixtyDayClose":879.24,"secType":"PLATE","market":"HK","turnoverRate":0.002066,"peRate":18.141358,"marketCap":610824762624,"floatMarketCap":505133911680,"timestamp":1790928487328,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":1,"down":16,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1194011215","title":"GenFleet-B (02595) Spends HK$3.1855 Million to Repurchase 116,000 Shares on September 28","url":"https://stock-news.laohu8.com/highlight/detail?id=1194011215","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194011215?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:00","pubTimestamp":1790589620,"startTime":"0","endTime":"0","summary":"GenFleet-B (02595) has announced that on September 28, 2026, it spent HK$3.1855 million to repurchase 116,000 shares.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595","BK1515","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670235579","title":"Sino Biopharma Unit Grants STADA Commercialization License for Pembrolizumab Biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2670235579","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670235579?lang=en_us&edition=fundamental","pubTime":"2026-09-28 17:53","pubTimestamp":1790589211,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical  unit Chia Tai Tianqing Pharmaceutical Group entered into a strategic biosimilars partnership with STADA Arzneimittel, a Monday bourse filing showed.Under the contract, Chia Tai Tianqing Pharma will grant STADA an exclusive license to commercialize pembrolizumab biosimilar TQB3570 in the European Union, Switzerland,the U.K., and the Commonwealth of Independent States.Chia Tai Tianqing Pharma will receive an upfront payment and be eligible for potential development, regulatory, and sales milestone payments of up to 53 million euros, alongside a double-digit profit share for the pembrolizumab biosimilar candidate.The parties also have options to add up to three additional biosimilar molecules across oncology and immunology indications.The company will develop and manufacture the candidates, while Germany-headquartered STADA will lead marketing and sales.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01177","BK1521","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1191","IE00BZ08YS42.EUR","BK1515","IE00BZ08YT58.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670528047","title":"Sino Biopharmaceutical - Stada to Hold Marketing Authorizations and Sales Rights in Licensed Territory, Options for US and GCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2670528047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670528047?lang=en_us&edition=fundamental","pubTime":"2026-09-28 16:46","pubTimestamp":1790585165,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45I0G0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BZ08YR35.GBP","01177","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","BK1589","BK1191","IE00BZ08YT58.USD","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670280479","title":"Sino Biopharmaceutical - Enter into Strategic Biosimilars Partnership with Stada","url":"https://stock-news.laohu8.com/highlight/detail?id=2670280479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670280479?lang=en_us&edition=fundamental","pubTime":"2026-09-28 16:46","pubTimestamp":1790585165,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45I0G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","IE00BZ08YS42.EUR","BK1521","BK1515","BK1589","01177","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670280476","title":"Sino Biopharmaceutical - Cttq Grants Stada Exclusive License for Pembrolizumab Biosimilar in EU, Switzerland, UK, CIS","url":"https://stock-news.laohu8.com/highlight/detail?id=2670280476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670280476?lang=en_us&edition=fundamental","pubTime":"2026-09-28 16:46","pubTimestamp":1790585165,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45I0G0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01177","BK1191","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1515","IE00BZ08YT58.USD","BK1521","IE00BZ08YR35.GBP","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670808280","title":"Sino Biopharmaceutical Stock Slides 1.3% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2670808280","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670808280?lang=en_us&edition=fundamental","pubTime":"2026-09-28 16:33","pubTimestamp":1790584380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. shed 1.3% to 5.50 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.5% to 24642.51.This was the stock's fifth consecutive day of losses.Sino Biopharmaceutical Ltd. closed 36% short of its 52-week high of HK$8.54, which the company reached Oct. 8.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 0.6% and Amgen Inc. remained unchanged.Trading volume totaled 57.5 million shares, compared to the 50-day average of 82.2 million shares.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00B4R5TH58.HKD","LU1057294990.SGD","LU0109394709.USD","BK1521","HK0000165453.HKD","LU0889565916.HKD","BK4533","IE00B2B36J28.USD","PBE","LU1571399168.USD","LU2468319806.SGD","LU2089984988.USD","LU0058720904.USD","01177","IE00BFTCPJ56.SGD","BK4599","LU1983299246.USD","BK4534","BK4139","BK4588","IE0002141913.USD","BBH","IBB","BIB","LU2112291526.USD","AMGN","IBBQ","LU0289739699.SGD","BK4581","91335","BK1191","IE00BZ08YS42.EUR","SG9999001440.SGD","PJP","BK1515","TBXU","IE00BJT1NW94.SGD","BK1589","IE00BZ08YT58.USD","LU2242652126.USD","BK4585","IE0009355771.USD","LU0868494617.USD","IE00BZ08YR35.GBP","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU1061106388.HKD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670228080","title":"JD Health International Stock Rises 1.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2670228080","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670228080?lang=en_us&edition=fundamental","pubTime":"2026-09-28 16:33","pubTimestamp":1790584380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of JD Health International Inc. rallied 1.3% to 35.54 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.5% to 24642.51.The stock's rise snapped a four-day losing streak.JD Health International Inc. closed 50% short of its 52-week high of HK$71.70, which the company achieved Jan. 15.Trading volume totaled 8.2 million shares, compared to the 50-day average of 8.5 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1142","BK1247","LU0456827905.SGD","LU0051755006.USD","86618","BK1591","BK1571","SGXZ62798434.SGD","SGXZ86797644.SGD","BK1615","BK1589","BK1583","06618","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132272624","title":"Healthcare Shows Resilience! Pharma ETF Huabao (562050) Rises Against the Market, Livzon Pharmaceutical Group Hits Limit Up! Medical Devices Show Localized Strength, Mindray and United Imaging Advance Together","url":"https://stock-news.laohu8.com/highlight/detail?id=1132272624","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132272624?lang=en_us&edition=fundamental","pubTime":"2026-09-28 13:22","pubTimestamp":1790572929,"startTime":"0","endTime":"0","summary":"On the first trading day after the Mid-Autumn Festival (September 28), A-shares underwent a deep correction, with the Shanghai Composite Index falling nearly 2% at one point. Pharmaceutical assets...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","562050","MEDX","PTH","RSPH","BK0239","GDOC","LNGR","159883","BK1161","LGHT","AGNG","BK0187","BK1515","BK1100","09996","159938","HART","BK0188","BK1583","000513","IEIH","09939","MDEV","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108038702","title":"Fosun Pharma Spends HK$1.0805 Million to Repurchase 62,000 Shares on September 25","url":"https://stock-news.laohu8.com/highlight/detail?id=1108038702","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108038702?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:30","pubTimestamp":1790555421,"startTime":"0","endTime":"0","summary":"Fosun Pharma (02196) issued an announcement stating that on September 25, 2026, the company spent HK$1.0805 million to repurchase 62,000 shares.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0196","02196","BK1191","BK0187","BK1593","BK0028","BK0012","BK0188","BK0239","600196","BK0175","BK1515","BK0183","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191497499","title":"Lazard Asset Management LLC Trims 738,800 Shares in Sinopharm (01099) at Approximately HK$15.1 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1191497499","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191497499?lang=en_us&edition=fundamental","pubTime":"2026-09-27 19:08","pubTimestamp":1790507292,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on September 21, Lazard Asset Management LLC reduced its holdings in Sinopharm (01099) by 738,800 shares at a price of HK$15.1035 per...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","BK1500","01099","BK1515","LU0640798160.USD","LU1115378108.SGD","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164509239","title":"FMR LLC Trims Sinopharm Stake by 732,400 Shares at About HK$15.01 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1164509239","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164509239?lang=en_us&edition=fundamental","pubTime":"2026-09-27 19:08","pubTimestamp":1790507291,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on September 21, FMR LLC reduced its holdings in Sinopharm (SEHK: 01099) by 732,400 shares at a price of HK$15.0147 per share, for a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099","BK1500","BK1515","LU0640798160.USD","EWH","BK1197","LU1115378108.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670446469","title":"JD Health International Stock Sheds 2.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2670446469","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670446469?lang=en_us&edition=fundamental","pubTime":"2026-09-25 16:30","pubTimestamp":1790325000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of JD Health International Inc. slid 2.0% to 35.08 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.0% to 24510.09.This was the stock's fourth consecutive day of losses.JD Health International Inc. closed 51% short of its 52-week high of HK$71.70, which the company achieved Jan. 15.Trading volume totaled 5.6 million shares, compared to the 50-day average of 8.6 million shares.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456827905.SGD","BK1247","BK1591","06618","LU0051755006.USD","SGXZ62798434.SGD","86618","BK1142","SGXZ86797644.SGD","BK1583","BK1589","BK1571","BK1615","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171106151","title":"Regulator Clarifies Insurers' Hong Kong Stock Connect ETF Investment Rules; Crealights' Southbound Stake Rises to 4.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171106151","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171106151?lang=en_us&edition=fundamental","pubTime":"2026-09-25 08:12","pubTimestamp":1790295146,"startTime":"0","endTime":"0","summary":"Several insurers recently received a letter clarifying the regulatory scope for insurance funds investing in Hong Kong Stock Connect ETFs. The document specifies that insurance institutions eligible...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","03933","LU0708995583.HKD","LU0287142896.SGD","SG9999012744.USD","SG9999003461.SGD","SG9999004220.SGD","LU2039709279.SGD","LU1206782309.USD","LU0314109678.HKD","BK1546","IE0008369823.USD","IE00BZ08YT58.USD","IE0032431581.USD","HK0000286598.CNH","IE00B5MMRT66.SGD","BK4550","LU1226287529.USD","LU0052750758.USD","LU1960683339.HKD","LU1152091754.HKD","LU0072913022.USD","BK1550","LU0211977185.USD","BK1170","LU1951186391.HKD","LU0871576103.HKD","LU0320764599.SGD","BK1184","BK1515","IE00B3M56506.USD","LU0501845795.SGD","LU1226288253.USD","LU2257852520.SGD","SG9999012736.USD","02628","IE0008368742.USD","BK1584","01191","LU0588546209.SGD","LU0307460666.USD","LU0169518387.USD","LU0039217434.USD","LU0880133367.SGD","LU1046422090.SGD","BK1230","IE00BZ08YR35.GBP","KCAI","LU2097828805.USD","LU1226288170.HKD","FDN","LU1807302812.USD","LU0140636845.USD","LU1328277881.USD","LU2097828474.EUR","KURE","SG9999012728.SGD","LU0173614495.USD","01093","LU2097828631.EUR","SG9999012710.SGD","LU0315179316.USD","IE00B031HY20.USD","BK4588","BK1205","LU1993786604.SGD","BK1537","LU1808992512.USD","03692","BK1583","BK1589","01133","LU0326950275.SGD","LU1152091168.USD","LU1008478684.HKD","IE00B543WZ88.USD","LU0531971595.HKD","LU1813983027.USD","VXUS","BK1191","BK1147","LU2097828557.USD","LU0164865239.USD","LU1226287792.SGD","00659","BK4585","LU0067412154.USD","IE00BZ08YS42.EUR","LU3063872942.SGD","FLHK","HK0000165453.HKD","LU1226287875.USD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669558491","title":"CSPC Pharmaceutical Says Phase III Trial of Becotatug Achieves Positive Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669558491","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669558491?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:01","pubTimestamp":1790262116,"startTime":"0","endTime":"0","summary":"BRIEF-CSPC Pharmaceutical Says Phase III Trial Of Becotatug Achieves Positive Topline ResultsSept 24 (Reuters)-CSPC PHARMACEUTICAL GROUP LIMITED1093.HK:PHASE III TRIAL OF BECOTATUG (JMT101) WITH OSIMERTINIB ACHIEVES POSITIVE TOPLINE RESULTSFurther company coverage:1093.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nFWN45G0DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0880133367.SGD","BK1191","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","LU1008478684.HKD","LU1226288170.HKD","LU1226287529.USD","LU1152091168.USD","LU1807302812.USD","BK1515","IE00BZ08YT58.USD","LU1951186391.HKD","IE00BZ08YS42.EUR","LU1328277881.USD","HK0000165453.HKD","BK1521","LU0315179316.USD","LU1813983027.USD","IE00B543WZ88.USD","LU2039709279.SGD","01093","LU1960683339.HKD","LU0067412154.USD","LU0072913022.USD","SG9999004220.SGD","KURE","LU1226287792.SGD","LU1152091754.HKD","LU1226287875.USD","LU0314109678.HKD","IE0008368742.USD","IE0008369823.USD","LU1993786604.SGD","LU0326950275.SGD","LU1226288253.USD","IE00B031HY20.USD","LU0140636845.USD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669498067","title":"CSPC Pharma's Phase III Trial of Lung Cancer Drug Combo Achieves Positive Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669498067","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669498067?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:55","pubTimestamp":1790254529,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group's  phase III trial of Becotatug in combination with osimertinib met its primary endpoint at a pre-specified interim analysis and achieved positive topline results.The drug combination was being tested for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.Compared with platinum-based chemotherapy in combination with pemetrexed, the treatment combination significantly prolonged the progression-free survival of patients and showed a trend of benefit in overall survival.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1960683339.HKD","KURE","LU0314109678.HKD","LU1951186391.HKD","01093","LU1226287529.USD","LU0880133367.SGD","IE00BZ08YS42.EUR","LU0072913022.USD","LU0315179316.USD","IE00BZ08YR35.GBP","IE0008368742.USD","IE00B543WZ88.USD","IE0008369823.USD","LU2039709279.SGD","LU1226288253.USD","LU1807302812.USD","BK1521","HK0000165453.HKD","SG9999004220.SGD","LU1008478684.HKD","LU0140636845.USD","IE00BZ08YT58.USD","LU1226287875.USD","LU1813983027.USD","LU0501845795.SGD","LU1152091754.HKD","LU1328277881.USD","LU1993786604.SGD","LU0067412154.USD","LU1226287792.SGD","IE00B031HY20.USD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU1152091168.USD","LU1226288170.HKD","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183769643","title":"CSPC Pharma's JMT101 Combined with Osimertinib Achieves Positive Topline Results in Phase III Trial for First-Line Treatment of EGFR ex20ins NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1183769643","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183769643?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:28","pubTimestamp":1790252894,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that the Phase III clinical trial of its developed becotatug (JMT101) in combination with osimertinib for the first-line treatment of locally advanced or metastatic...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU0315179316.USD","LU0140636845.USD","SG9999004220.SGD","LU1152091754.HKD","IBBJ","LU0314109678.HKD","BK1515","LU0501845795.SGD","LU1226287529.USD","LU1993786604.SGD","LU0072913022.USD","BMED","LU0880133367.SGD","LU1813983027.USD","LU2039709279.SGD","KURE","LU1152091168.USD","LU1951186391.HKD","PSYK","IE0008368742.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","MDTX","01093","LU1328277881.USD","BK1521","BK1191","LU1226287875.USD","LU1226288253.USD","LU1807302812.USD","LU1008478684.HKD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU1226288170.HKD","LU1226287792.SGD","LU1960683339.HKD","LU0326950275.SGD","IE0008369823.USD","IE00BZ08YR35.GBP","LU0067412154.USD","IE00B543WZ88.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669460157","title":"CSPC Pharmaceutical - Phase Iii Trial of Becotatug (Jmt101) with Osimertinib Achieves Positive Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669460157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669460157?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:08","pubTimestamp":1790251730,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nFWN45G0DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0501845795.SGD","IE00B031HY20.USD","LU1152091754.HKD","LU1008478684.HKD","LU1226287529.USD","LU1807302812.USD","KURE","SG9999004220.SGD","IE00BZ08YT58.USD","LU2039709279.SGD","LU1960683339.HKD","IE00B543WZ88.USD","LU0314109678.HKD","LU0315179316.USD","IE0008368742.USD","LU0067412154.USD","LU0880133367.SGD","LU1226287875.USD","LU1152091168.USD","IE00BZ08YS42.EUR","LU1328277881.USD","IE00B5MMRT66.SGD","LU0140636845.USD","HK0000165453.HKD","LU1226287792.SGD","BK1515","LU1226288253.USD","01093","LU1226288170.HKD","BK1521","LU0326950275.SGD","IE0008369823.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU1951186391.HKD","LU0072913022.USD","LU1993786604.SGD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132416534","title":"Dizal Pharmaceutical Executives Including CFO Lu Hongbin Plan to Reduce Shareholdings","url":"https://stock-news.laohu8.com/highlight/detail?id=1132416534","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132416534?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:01","pubTimestamp":1790251288,"startTime":"0","endTime":"0","summary":"Dizal Pharmaceutical has released a new announcement stating that five senior executives, including Chief Financial Officer Lu Hongbin, Deputy General Manager Chen Suqin, QINGBEIZENG, HONCHUNGTSUI,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09939","BK1515","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669246984","title":"CSPC Pharm Begins Phase III Breast Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669246984","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669246984?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:42","pubTimestamp":1790242928,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) officially initiated a phase III trial of docetaxel for injection at the first centre in China, according to a Thursday bourse filing.The study will evaluate the safety and efficacy of the drug in patients with advanced breast cancer, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2039709279.SGD","LU0501845795.SGD","BK1191","LU1152091168.USD","LU1960683339.HKD","BK1521","LU0072913022.USD","IE00BZ08YT58.USD","LU1226287875.USD","IE00B031HY20.USD","LU1226287529.USD","LU0314109678.HKD","LU1008478684.HKD","LU1807302812.USD","LU1152091754.HKD","LU1993786604.SGD","IE0008369823.USD","IE00BZ08YS42.EUR","HK0000165453.HKD","IE0008368742.USD","LU0067412154.USD","KURE","LU0326950275.SGD","LU1226287792.SGD","LU0880133367.SGD","LU0140636845.USD","LU1226288253.USD","IE00B543WZ88.USD","BK1515","LU1951186391.HKD","SG9999004220.SGD","LU1328277881.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU0315179316.USD","01093","LU1226288170.HKD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157621104","title":"Hubei Tycoon Ai Luming Detained: Who Is Hurt by Tiangan Asset Management's 3.5 Billion Yuan Debt?","url":"https://stock-news.laohu8.com/highlight/detail?id=1157621104","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157621104?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:21","pubTimestamp":1790241693,"startTime":"0","endTime":"0","summary":"On the evening of September 18, a public announcement from Wuhan Sante Cableway Group Co.,Ltd. (002159.SZ) pushed the \"Dangdai Group\" and its founder Ai Luming back into the spotlight once again.The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","BK0102","BK0028","BK0241","BK1161","BK0188","BK0040","BK0185","BK1574","002159","BK4547","AMC","600079","BK1515","BK0096","BK0012","BK0239","09939","BK4108"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":4,"totalSize":155,"code":"91000000","status":"200"}]}}